[go: up one dir, main page]

IL146459A0 - Previns as specific inhibitors and therapeutic agents for botulinum toxin b and tetanus neurotoxins - Google Patents

Previns as specific inhibitors and therapeutic agents for botulinum toxin b and tetanus neurotoxins

Info

Publication number
IL146459A0
IL146459A0 IL14645900A IL14645900A IL146459A0 IL 146459 A0 IL146459 A0 IL 146459A0 IL 14645900 A IL14645900 A IL 14645900A IL 14645900 A IL14645900 A IL 14645900A IL 146459 A0 IL146459 A0 IL 146459A0
Authority
IL
Israel
Prior art keywords
sub
line
formulae
amino acid
modified form
Prior art date
Application number
IL14645900A
Other languages
English (en)
Original Assignee
Us Army Med Res Mat Command
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Army Med Res Mat Command filed Critical Us Army Med Res Mat Command
Publication of IL146459A0 publication Critical patent/IL146459A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL14645900A 1999-05-17 2000-05-15 Previns as specific inhibitors and therapeutic agents for botulinum toxin b and tetanus neurotoxins IL146459A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13444699P 1999-05-17 1999-05-17
PCT/US2000/013215 WO2000069891A2 (en) 1999-05-17 2000-05-15 Previns as specific inhibitors and therapeutic agents for botulinum toxin b and tetanus neurotoxins

Publications (1)

Publication Number Publication Date
IL146459A0 true IL146459A0 (en) 2002-07-25

Family

ID=22463433

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14645900A IL146459A0 (en) 1999-05-17 2000-05-15 Previns as specific inhibitors and therapeutic agents for botulinum toxin b and tetanus neurotoxins

Country Status (9)

Country Link
US (3) US6573244B1 (xx)
EP (1) EP1179010B1 (xx)
JP (1) JP2003501012A (xx)
AT (1) ATE365173T1 (xx)
AU (1) AU772985B2 (xx)
CA (1) CA2372304A1 (xx)
DE (1) DE60035270D1 (xx)
IL (1) IL146459A0 (xx)
WO (1) WO2000069891A2 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US7563874B2 (en) 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US6713444B1 (en) * 1999-05-14 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Buforin I as a specific inhibitor and therapeutic agent for botulinum toxin B and tetanus neurotoxins
US6573244B1 (en) * 1999-05-17 2003-06-03 The United States Of America As Represented By The Secretary Of The Army Previns as specific inhibitors and therapeutic agents for Botulinum toxin B and Tetanus neurotoxins
DE10038511A1 (de) * 2000-08-08 2002-02-21 Bhs Corr Masch & Anlagenbau Längs-Bearbeitungs-Maschine für Wellpappe-Bahnen
US7332567B2 (en) * 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7350590B2 (en) * 2002-11-05 2008-04-01 Weatherford/Lamb, Inc. Instrumentation for a downhole deployment valve
US7700738B2 (en) 2005-01-27 2010-04-20 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US8658372B2 (en) * 2005-06-10 2014-02-25 The United States Of America, As Represented By The Secretary Of The Navy Affinity-based detection of biological targets
US20070154448A1 (en) 2005-11-22 2007-07-05 Ted Reid Methods and compositions using Substance P to promote wound healing
WO2009008916A2 (en) 2007-03-22 2009-01-15 The Regents Of The University Of Californina Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
WO2010014854A2 (en) 2008-07-31 2010-02-04 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
WO2012047427A2 (en) 2010-08-31 2012-04-12 The Regents Of The University Of California Antibodies for botulinum neurotoxins
KR20240023684A (ko) 2016-09-13 2024-02-22 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4059693A (en) * 1976-06-11 1977-11-22 University Patents, Inc. Analgesic action of substance P
US5137873A (en) * 1990-07-27 1992-08-11 The Children's Medical Center Corporation Substance p and tachykinin agonists for treatment of alzheimer's disease
EP0593615B1 (en) * 1991-07-10 1996-01-31 MERCK SHARP & DOHME LTD. Aromatic compounds, compositions containing them and their use in therapy
WO1993001159A1 (en) * 1991-07-10 1993-01-21 Merck Sharp & Dohme Limited Fused tricyclic compounds, pharmaceutical compositions containing them and their use in therapy
AU3716997A (en) * 1996-07-17 1998-02-09 Merck & Co., Inc. Alteration of circadian rhythmicity with a tachykinin antagonist
US5945508A (en) * 1996-07-23 1999-08-31 Witten; Mark L. Substance P treatment for immunostimulation
KR100263583B1 (ko) * 1997-05-28 2000-08-01 박종헌 항균 펩타이드의 대량 제조방법 및 그에 유용한 플라즈미드 벡타
KR100314721B1 (ko) * 1998-01-22 2001-11-23 김일웅 생물학적 활성이 있는 신규한 펩타이드
US6573244B1 (en) * 1999-05-17 2003-06-03 The United States Of America As Represented By The Secretary Of The Army Previns as specific inhibitors and therapeutic agents for Botulinum toxin B and Tetanus neurotoxins

Also Published As

Publication number Publication date
US20060247176A1 (en) 2006-11-02
AU772985B2 (en) 2004-05-13
US20050113304A1 (en) 2005-05-26
DE60035270D1 (de) 2007-08-02
US6573244B1 (en) 2003-06-03
EP1179010A2 (en) 2002-02-13
ATE365173T1 (de) 2007-07-15
WO2000069891A3 (en) 2001-07-19
WO2000069891A9 (en) 2002-07-04
US7375079B2 (en) 2008-05-20
JP2003501012A (ja) 2003-01-14
AU5013600A (en) 2000-12-05
CA2372304A1 (en) 2000-11-23
WO2000069891A2 (en) 2000-11-23
EP1179010B1 (en) 2007-06-20

Similar Documents

Publication Publication Date Title
IL146459A0 (en) Previns as specific inhibitors and therapeutic agents for botulinum toxin b and tetanus neurotoxins
NO302474B1 (no) Sakarinderivater, farmasöytisk sammensetning og anvendelse derav
NZ520659A (en) Xylanase variants having altered sensitivity to xylanase inhibitors caused by mutations in the lid region
JP2001520045A5 (xx)
EE200100487A (et) Uudsed ühendid ja kompositsioonid proteaasiinhibiitoritena
NO930517L (no) Benzimidazolylderivater, legemidler inneholdende disse, og fremgangsmaate for deres fremstilling
MX9704439A (es) Derivados heterociclicos aromaticos como inhibidores de enzima.
ATE335813T1 (de) Protease varianten
PT1311285E (pt) Composicao farmaceutica liquida contendo um derivado de eritropoietina
AU617875B2 (en) Novel peptidase inhibitors
NZ501346A (en) Valinyl aromatic beta amino acid dipeptide compounds having fungicidal activity and their agronomic use
BR9713465A (pt) Inibidores metalotprotease de amina cìclica sibstituìda
MY137301A (en) Peptide analogs as irreversible interleukin-1b protease inhibitors
ATE168130T1 (de) Stabilisierte enzyme und waschmittelzusammensetzungen
DK0535091T3 (da) Knogleinducerende farmaceutiske formuleringer
DK1653989T3 (da) Antibakteriel sammensætning især mod gramnegative bakterier og som omfatter et peptid og et fortrinsvist hydrofobt antibakterielt middel
DE69033699D1 (de) Gegenüber eigenen inhibitoren resistente t-pa mutanten
DE69232929D1 (de) Saccharinderivate als proteolytische Enzyminhibitoren
BR9811099A (pt) Inibidores de urocinase
BR9911891A (pt) Proteases fundidas com variantes de inibidor de subtilisina de streptomyces
NZ302072A (en) 1,3-diamino propyl stereomeric derivatives and organic acid and inorganic salts of their amine intermediates in the preparation of retroviral protease inhibitors
AU5232886A (en) Serine protease inhibitors and methods for isolation of same
LV10108A (lv) Sunu proliferacijas inhibitori farmaceitiska kompozicija savienojumu iegusanas metode sunu proliferacijas inhibesanas panemieni
WO2000069895A3 (en) Bufornin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins
IL162314A0 (en) Use of pyridine-2,4-dicarboxylic acid diamides andof pyrimidine-4,6-dicarboxylic acid diamides for selective collagenase inhibition